We are live on ! Find out more
GLMD icon

Galmed Pharmaceuticals
GLMD

10 hedge funds and large institutions have $57.6K invested in Galmed Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 10 → 10 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

0.1% less ownership

Funds ownership: 0.15% → 0.05% (-0.1%)

77% less capital invested

Capital invested by funds: $249K → $57.6K (-$191K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 4

Holders
10
Holders Change
–
Holders Change %
0%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
4
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TSS
Two Sigma Securities
New York
+$6.13K
2
UBS Group
UBS Group
Switzerland
+$865

Top Sellers

Rank Fund Capital Flow
1
CH
CVI Holdings
Delaware
-$73.1K
2
Walleye Capital
Walleye Capital
New York
-$27.5K
3
Morgan Stanley
Morgan Stanley
New York
-$25.5K
4
Two Sigma Investments
Two Sigma Investments
New York
-$10.7K
5
Two Sigma Advisers
Two Sigma Advisers
New York
-$8.33K

GLMD Hedge Fund Activity: Q1 2024 in Review

10 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q1 2024, worth a combined $57.6K — down 77% from $249K a quarter earlier.

Fund positioning in GLMD was balanced in Q1 2024: 2 funds opened new positions, 2 closed out, 0 added to existing stakes and 4 trimmed.

The largest buyer was Two Sigma Securities, opening a new position worth an estimated $6.13K. The largest seller was CVI Holdings, cutting an estimated $73.1K.

  • 10 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q1 2024, unchanged from Q4 2023.
  • Funds reported $57.6K of Galmed Pharmaceuticals stock for Q1 2024, down 77% quarter-over-quarter.
  • 2 funds opened new Galmed Pharmaceuticals positions in Q1 2024 and 2 closed out, a net change of 0 holders.
  • The largest Galmed Pharmaceuticals buyer in Q1 2024 was Two Sigma Securities, an estimated $6.13K added.
  • The largest Galmed Pharmaceuticals seller in Q1 2024 was CVI Holdings, an estimated $73.1K sold.

Based on aggregated 13F filings for Q1 2024.